Human CLDN1 Knockout A-431 Cell Line

Description

Human CLDN1 Knockout A-431 Cell Line is engineered from human epidermoid carcinoma A-431 cells using CRISPR/Cas9 technology to disrupt the Claudin 1 (CLDN1) gene, a tight junction protein critical for epidermal barrier function and cell polarity. This knockout model exhibits compromised tight junction integrity and increased paracellular permeability while maintaining A-431 cells’ characteristic epithelial morphology. The cell line serves as a valuable tool for studying skin barrier disorders (such as ichthyosis and atopic dermatitis), viral entry mechanisms (including HCV and Dengue virus infection), and cancer metastasis, particularly in research involving epithelial barrier dysfunction and cell-cell adhesion. Maintained at low passage numbers (<P20) with genetic stability, the knockout efficiency is validated through genomic PCR, Sanger sequencing, and immunofluorescence staining demonstrating loss of tight junction strands. Rigorous quality control confirms the cell line is free of contamination from HIV-1, HBV, HCV, Syphilis, mycoplasma, fungi, yeast, and bacteria.

Application

• FOR RESEARCH USE ONLY
  

• The Human CLDN1 Knockout A-431 Cell Line is a valuable model for studying tight junction integrity and epithelial barrier function in cancer. This engineered system enables investigation of claudin-1’s dual roles in cell adhesion and signaling pathways. Researchers utilize this knockout line to examine disrupted paracellular transport and enhanced metastatic behavior in squamous cell carcinoma. The cell line provides a controlled platform for evaluating therapeutic strategies targeting tight junction proteins in epithelial malignancies and inflammatory skin disorders.